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Abstract
In many areas of clinical investigation there is great interest in identifying and validating surrogate endpoints,
biomarkers that can be measured a relatively short time after a treatment has been administered and that can reliably
predict the effect of treatment on the clinical outcome of interest. However, despite dramatic advances in the ability
to measure biomarkers, the recent history of clinical research is littered with failed surrogates. In this paper, we present
a statistical perspective on why identifying surrogate endpoints is so difficult. We view the problem from the
framework of causal inference, with a particular focus on the technique of principal stratification (PS), an approach
which is appealing because the resulting estimands are not biased by unmeasured confounding. In many settings, PS
estimands are not statistically identifiable and their degree of non-identifiability can be thought of as representing the
statistical difficulty of assessing the surrogate value of a biomarker. In this work, we examine the identifiability issue
and present key simplifying assumptions and enhanced study designs that enable the partial or full identification of
PS estimands. We also present example situations where these assumptions and designs may or may not be feasible,
providing insight into the problem characteristics which make the statistical evaluation of surrogate endpoints so
challenging.
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Introduction
Background
Randomized clinical trials are well-suited to answering
the question of whether a particular treatment affects
an outcome. Randomization ensures that on average, all
covariates–whether measurable or unmeasurable, known
or unknown–are equally distributed between treatment
groups. Differences in outcomes between these groups
can thus be attributed to the treatment alone, and com-
parisons of randomized treatment groups yield what are
rightly termed causal effects. But clinical trials are often
lengthy and costly, particularly when the outcome of inter-
est is relatively rare (e.g., occurrence of myocardial infarc-
tion, infection with HIV). Long trials provide high-quality
evidence about the efficacy of treatments, but they can
delay research progress as scientists must wait for results
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to learn how treatments might be improved. As a result,
in many areas of clinical investigation there is great inter-
est in identifying surrogate endpoints, outcomes (often
biomarkers) that can be measured a relatively short time
after a treatment has been administered and which reli-
ably predict the effects of treatment on clinical outcomes
of interest.
A validated surrogate permits a future treatment to
be evaluated much more quickly, since observed effects
on the surrogate can be translated into an expected
level of clinical efficacy without the need to carry the
study forward and record clinical outcomes. A valid sur-
rogate can also give insight into the biological mecha-
nisms of treatment. However, declaring a biomarker to
be a surrogate when it is merely correlated with clinical
risk can divert valuable resources toward scientific dead
ends. Treatments targeting candidate surrogate biomark-
ers have often been ineffective, with failures ranging
across diseases including cardiovascular disease, cancer,
and osteoporosis [1].
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Because a candidate surrogate is measured some time
after treatment has been administered, its levels may be
affected by treatment, thereby introducing possible con-
founding of the association between the surrogate and the
outcome – see, e.g., Figure one of Wolfson and Gilbert
[2]. This confounding, also termed selection bias, can
invalidate traditional analyses which estimate the effect of
treatment on the outcome conditional on the level of the
candidate surrogate. It is particularly difficult to control
for this confounding by adjusting for baseline covariates
since candidate surrogate biomarkers often are themselves
poorly understood and the relevant adjustment variables
are unclear. The possible influence of unmeasured con-
founders within individual studies can be mitigated by
meta-analytic techniques [3,4], but the surrogate endpoint
problem often will be of interest in situations where it
is too costly or too time-consuming to perform multiple
trials measuring both the biomarker and the clinical out-
come. For this paper, we therefore restrict attention to
approaches for assessing surrogate value using data from
a single trial.
The potential for unmeasured confounding in the sur-
rogate endpoint problem has motivated the development
and application of statistical methods for causal infer-
ence in this setting. These methods propose estimands
based on counterfactuals–also called potential outcomes–
whose basic theory is described elsewhere [5,6]. The
key characteristic of these causal estimands is that they
quantify within-person treatment effects, which are by
definition free from confounding.
Joffe and Greene [7] identified four approaches for eval-
uation of surrogate outcomes and grouped them into two
paradigms. The causal effects paradigm considers individ-
ual treatment effects when the candidate surrogate is fixed
at different values. Prentice [8] described a set of crite-
ria for validating a surrogate using observed data from a
single randomized trial; the criteria are closely related to
those proposed by Baron and Kenny [9] to assess medi-
ation, and have been widely applied (e.g., [10-12]). More
recent work [13-16] has focused on quantifying counter-
factual direct and indirect effects of treatment, and though
most of this work is framed in terms of estimating medi-
ating effects, it is also applicable to surrogate endpoint
assessment as strong mediators are likely to be good sur-
rogates although the converse need not be true [17]. How-
ever, some authors [18] have criticized this approach to
evaluating surrogate endpoints on the basis that it posits
a hypothetical manipulation of the biomarker value which
may be implausible.
The second paradigm described by Joffe and Greene
is the causal association paradigm, which considers the
association between the effect of treatment on the surro-
gate and the effect of treatment on the outcome. The main
strategy under this paradigm is principal stratification,
which was proposed by Frangakis and Rubin [18] and
has been developed further in a number of recent papers
[2,19-22]. Evaluating surrogacy via principal stratification
relies on partioning subjects according to the (counter-
factual) biomarker values that would have been observed
under assignment to the control and treatment arms.
Since the resulting principal strata are assumed to be
independent of treatment (i.e., they are baseline sub-
ject characteristics), treatment remains randomized and
hence causal effects can be estimated through calcula-
tion of a contrast in outcomes between those assigned to
treatment and to control within each stratum. The final
assessment of surrogate value involves quantifying the
causal effects of treatment within defined sets of prin-
cipal strata. Because each participant is assigned either
to the control or to the treatment arm, only one of the
two potential biomarker values in the pair defining the
stratum is known; the other is counterfactual. Principal
stratification estimands are therefore not usually statis-
tically identifiable unless strong, untestable assumptions
are made.
Previous work has focused on describing assumptions
and developing PS-based approaches in specific scenarios
[2,19]. This paper takes a broader view by characteriz-
ing the key scientific, statistical and study design aspects
that challenge the identification of principal stratifica-
tion estimands for quantifying the surrogate value of a
biomarker. In each specific scenario, the degree of sta-
tistical nonidentifiability of PS estimands can be viewed
as a rough measure of the inherent difficult of the statis-
tical evaluation of surrogate endpoints in that scenario.
Exploring the identifiability of PS estimands can therefore
explain why medical researchers have been relatively suc-
cessful in identifying surrogates in some contexts but not
others. And, perhaps more importantly, understanding
the aspects of a scientific problem which help or hinder
the statistical assessment of surrogate value can anticipate
the degree to which novel study designs and statistical
analyses will be helpful in the search for surrogate end-
points. When the key assumptions described below are
plausible, causal PS analyses may be vital for identifying
promising surrogates and it is advisable to conduct large
endpoint-driven studies which collect the biomarker data
necessary to enable these analyses. In settings where many
of the assumptions are violated, causal PS analyses may
have relatively little to offer and researchers should pursue
other approaches–such as additional laboratory exper-
iments and mechanistic studies–to gain insight about
potential surrogate biomarkers.
In the Section “Principal stratification for assessing sur-
rogate value”, we introduce notation as well as present
the key principal stratification estimands and criteria
for assessing surrogate value. The Section “Simplify-
ing assumptions” describes three common simplifying
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assumptions the plausibility of which can significantly
influence the statistical identifiability of principal strati-
fication estimands. The Section “Auxiliary data and aug-
mented study design” outlines how auxiliary data and
novel study designs can be used to identify estimands of
interest. In the Section “Example scenarios”, we present
four example scenarios that illustrate how the charac-
teristics of the disease process, study population, and
trial design can combine to make the statistical assess-
ment of surrogate endpoints relatively straightforward or
extremely difficult. We conclude with a brief discussion in
Section “Conclusion”.
Principal stratification for assessing surrogate
value
Notation and setup
Consider a randomized trial where subjects i = 1, . . . , n
randomly are assigned at baseline to one of two treat-
ments (Zi = 0, 1) and followed for a binary outcome Yi.
A biomarker, Si, is measured at some time τ > 0, and
we assume that τ is the same for all subjects. Biomark-
ers might include values derived from a lab-based assay
or a patient’s health status at τ . In some situations, due
to the occurrence of the clinical outcome Y prior to τ or
due to other reasons, it may not be possible to measure
Si at τ . For example, in HIV vaccine trials where Yi indi-
cates infection with HIV and Si is some immune response
to the vaccine, infection with HIV prior to τ precludes
the meaningful measurement of Si at τ . We let Aτi denote
whether the biomarker is observable at τ . When Aτi = 0,
Si is undefined, which we denote Si = . Note that Si
may be unobserved but not undefined in cases of drop-out
or loss-to-follow-up; we do not discuss the complexities
of handling missing but well-defined biomarker values in
this paper. Lastly, we assume that a vector of baseline
covariatesWi is available for each subject.
Principal stratification
In our work, we let
(
Aτiz, Siz,Yiz
)
be the counterfactual
values of
(
Aτi , Si,Yi
)
under treatment assignment Zi =
z for each study participant i. For simplicity of presen-
tation, we generally suppress the subscript i. Note the
distinction between these counterfactuals, which describe
potential outcomes under different settings of Z, and
those employed by, e.g., Robins and Greenland [23], which
refer to potential outcomes when both Z and S are set to
certain values.
For assessing surrogate value in the context of a ran-
domized trial, Frangakis and Rubin [18] suggested com-
paring the treatment effect on the outcome of interest
within two classes of principal strata:
G1 : {{S0, S1} : S0 = S1} and G2 : {{S0, S1} : S0 = S1}
Within these strata–which are not affected by treat-
ment and hence play the same role as baseline covariate–
treatment assignments remain randomized and hence it
is trivial to estimate the causal effect of treatment. For a
good surrogate, we hope to see a small or no treatment
effect within principal strata from G1, i.e., those in which
subjects experience no causal treatment effect on S, and
some treatment effect on the outcome within principal
strata from G2, i.e., those in which there is some treatment
effect on S.
Gilbert and Hudgens [19] extended on Frangakis and
Rubin’s work, and proposed to assess surrogate value
based on contrasts of the estimands
R0(S0, S1) ≡ P
(
Y0 = 1 | S0, S1,Aτ0 = Aτ1 = 1
)
and (1)
R1(S0, S1) ≡ P
(
Y1 = 1 | S0, S1,Aτ0 = Aτ1 = 1
)
. (2)
The conditioning event
{
Aτ0 = Aτ1 = 1
}
is necessary to
ensure that the joint values of (S0, S1) are well defined.
Based on these estimands, Gilbert and Hudgens defined
a principal surrogate as a biomarker satisfying Average
Causal Necessity and Average Causal Sufficiency:
Average causal necessity: R0(S0, S1) = R1(S0, S1) for
all S1 = S0.
Average causal sufficiency: There exists a constant
C ≥ 0 such that R1(S0, S1) = R0(S0, S1) for all |S0 − S1| >
C.
Wolfson and Gilbert [2] considered the identifiability
and estimation of Equations 1 and (2) in the context of
HIV vaccine trials. Here, we explore the identifiability of
these estimands in a wider variety of contexts.
Basic assumptions
In what follows, we describe several basic assump-
tions which are generally uncontroversial in the random-
ized trial setting. Without these assumptions, estimation
would be virtually impossible; the remainder of this paper
focuses on stronger assumptions that may be defensible in
certain settings and that can help identify estimands for
assessing surrogate value. The basic assumptions are:
Stable unit treatment value assumption (SUTVA):
1. [No interference] The potential outcomes(
Y0,Y1,Aτ0,Aτ1, S0, S1
)
for one subject are
independent of the treatment assignments of other
subjects, i.e., there is no “interference” between
experimental units.
2. [Consistency] For an individual receiving treatment
Z = z and with observed outcome Y , we have
Y = Yz, i.e., the observed outcome is equal to the
potential outcome under the treatment actually
received.
Ignorable treatment assignments: Z is independent of(
Y0,Y1,Aτ0,Aτ1, S0, S1
)
.
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The validity of the “No Interference” part of SUTVA
may be questioned when the Y represents infection with
a communicable disease, but it is defensible in these set-
tings if a trial enrolls a small fraction of the at-risk pop-
ulation. Work by Hudgens and Halloran [24] discusses
relaxation of SUTVA. Ignorable Treatment Assignments
will generally hold in a randomized trial where blinding is
maintained.
Estimands and identifiability
In what follows, we study the risk estimands R1 and R0
under a variety of scenarios and assumptions.We focus on
the concept of nonparametric identifiability, i.e., whether
it is possible to obtain arbitrarily precise estimates of these
quantities given an infinite sample size, making no fur-
ther assumptions regarding the data distribution. If S0
and S1 respectively were to take on discrete values in
{s01, s02, . . . , s0K } and {s11, s12, . . . , s1K }, then assuming a
sufficiently large sample size, R0 and R1 would be non-
parametrically identifiable if R0
(
s0j, s1k
)
and R1
(
s0j, s1k
)
could be estimated precisely from observed data for all j
and k.
The nonparametric identifiability properties of R1 and
R0 can be understood by applying Bayes Rule:
R1 (s0, s1)= f
(
s0, s1|Y1=1,Aτ0 =Aτ1 =1
)
P
(
Y1=1|Aτ0 =Aτ1 =1
)
f
(
s0, s1|Aτ0 =Aτ1 =1
)
(3)
R0(s0, s1)= f
(
s0, s1|Y0=1,Aτ0 =Aτ1 =1
)
P
(
Y0=1|Aτ0 =Aτ1 =1
)
f
(
s0, s1|Aτ0 = Aτ1 =1
)
(4)
where f (s0, s1 | ·) and f (s0, s1) are joint densities (or prob-
ability mass functions) of (S0, S1). For simplicity, we
assume that these densities or p.m.f.’s exist.
To evaluate Average Causal Necessity and Sufficiency,
one must contrast the risks R1(s0, s1) and R0(s0, s1) for dif-
ferent values of (s0, s1). ACN and ACS above are stated in
terms of the risk difference,
RD(s0, s1)
=R1(s0, s1) − R0(s0, s1)
= [ f (s0, s1|Y1=1,Aτ0 =Aτ1 =1
)
P
(
Y1=1|Aτ0 =Aτ1 =1
)
−f (s0, s1|Y0=1,Aτ0 =Aτ1 =1
)
P
(
Y0=1|Aτ0 =Aτ1 =1
)]
/f
(
s0, s1|Aτ0 =Aτ1 =1
)
(5)
They may also be stated in terms of the relative risk,
RR(s0, s1)= R1(s0, s1)R0(s0, s1)
= f
(
s0, s1|Y1=1,Aτ0 =Aτ1 =1
)
P
(
Y1=1|Aτ0 =Aτ1 =1
)
f
(
s0, s1|Y0=1,Aτ0 =Aτ1 =1
)
P
(
Y0=1|Aτ0 =Aτ1 =1
)
(6)
where ACN holds if RD(s0, s1) = 0 ≡ RR(s0, s1) = 1 for
s1 = s0 and ACS holds if RD(s0, s1) = 0 ≡ RR(s0, s1) = 1
for s1 = s0.
In the most general case where no assumptions beyond
the Basic Assumptions above are made, neither R1, R0,
nor their contrasts RD and RR are statistically iden-
tifiable. This is clear since none of the terms on the
right-hand sides of (3)-(6) is identifiable: Neither
(
Aτ1,Aτ0
)
nor (S0, S1) can be observed simultaneously on a sub-
ject, hence observed data do not reveal membership in
the stratum defined by Aτ1 = Aτ0 = 1 nor do they
allow estimation of the joint distribution of S0 and S1.
In the next section, we discuss assumptions that allow
some or all of the expressions in (3)-(6) to be identified
from observed data, and describe situations in which these
assumptions may be plausible. This will lead naturally to
Section “Example scenarios”, where we describe scenarios
that vary according to the inherent difficulty of identifying
principal surrogate estimands and hence evaluating the
surrogate value of biomarkers.
Simplifying assumptions
We begin with a fundamental simplifying assumption
without which it is very difficult to achieve statistical
identifiability of R0 and R1:
[SA1] The biomarker S is defined on all subjects at
time τ , i.e., Aτ = Aτ0 = Aτ1 = 1 for all subjects.
[SA1] is likely to hold in situations where S can be mea-
sured shortly after treatment is administered at baseline,
and (trivially) when S is an intermediate outcome, e.g.,
two-year progression-free survival with prostate cancer
when the clinical outcome of interest is five-year overall
survival.
If [SA1] holds, there is no need to condition on
(
Aτ0,Aτ1
)
and hence (3)-(6) simplify to
R1(s0, s1)= f (s0, s1 |Y1 = 1)P(Y1 = 1)f (s0, s1) (7)
R0(s0, s1)= f (s0, s1 |Y0 = 1)P(Y0 = 1)f (s0, s1) (8)
RD(s0, s1)= f(s0, s1|Y1=1)P(Y1=1)−f (s0, s1|Y0=1)P(Y0=1)f (s0, s1)
(9)
RR(s0, s1)= f (s0, s1 |Y1 = 1)P(Y1 = 1)f (s0, s1 |Y0 = 1)P(Y0 = 1) (10)
By the Basic Assumptions, P(Y1 = 1) and P(Y0 = 1) are
identifiable and can be estimated as the sample mean of Y
among subjects assigned to Z = 1 and Z = 0, respectively.
The joint densities denoted by f remain non-identifiable,
but the subgroups within which these densities are to be
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estimated (Y1 = 1 and Y0 = 1) are identified. While [SA1]
must hold exactly to achieve simplifications of (7)-(10),
if the proportion of subjects with Aτ = 0 is very small
then it may be plausible to discard these subjects from the
analysis and proceed under [SA1].
[SA1] represents a first “layer” of non-identifiability,
below which lie additional identifiability challenges.
Hence, for the remainder of this section the estimands we
present implicitly condition on Aτ0 = Aτ1 = 1.
[SA2] Constant biomarker values under placebo
(S0 = c)
Sometimes, the task of imputing the joint biomarker val-
ues (S0, S1) is made simpler by placing restrictions on their
joint distribution. These restrictions may reflect inherent
features of the biomarkers themselves, or the manner in
which treatment and biomarkers interact. One specific
restriction that aids identifiability is based on the assump-
tion that S0 = c for all subjects, i.e., subjects receiving
the placebo achieve the same (often null) biomarker value.
This assumption may be plausible when the biomarker of
interest directly quantifies response to treatment and has
little natural variability absent that treatment, for exam-
ple if S were the serum concentration of a particular drug
metabolite which does not naturally occur in the body.
Under [SA2], the principal strata (S0, S1) = (c, S1) and
thus are defined fully by S1. When [SA1] and [SA2] both
hold, (7)-(10) further simplifies to
R1(s1) = f (s1 | Y1 = 1)P(Y1 = 1)f (s1) (11)
R0(s1) = f (s1 | Y0 = 1)P(Y0 = 1)f (s1) (12)
RD(s1)= f (s1|Y1=1)P(Y1=1) − f (s1|Y0=1)P(Y0=1)f (s1)
(13)
RR(s1) = f (s1 | Y1 = 1)P(Y1 = 1)f (s1 | Y0 = 1)P(Y0 = 1) (14)
Since (11) involves only counterfactuals observed on
subjects with Z = 1, R1 is statistically identifiable using
subjects assigned to treatment Z = 1. For example,
f (s1 | Y1 = 1) can be estimated non-parametrically as the
distribution of biomarker responses among treated sub-
jects who experienced the outcome (Y = 1 ⇒ Y1 = 1),
and f (s1) from biomarker responses among all treated
subjects. R0,RD, and RR remain nonidentifiable because
S1 is unobserved among subjects with Z = 0 and
Y0 is unobserved among those with Z = 1, so that
f (s1 | Y0 = 1) cannot be estimated from observed data.
But even without further assumptions it is relatively
straightforward to implement a sensitivity analysis which
quantifies how the distribution of S1 | Y0 = 1 differs
from the overall distribution of S1. An open-source web
application for R that provides a graphical interface for
sensitivity analysis under assumptions [SA1] and [SA2] is
available at http://z.umn.edu/CESensApp.
[SA3] Monotonic treatment effect
Monotonicity assumptions restrict the joint distribu-
tions of counterfactuals by positing that they take on
systematically lower (or higher) values under particular
conditions. They are commonly applied in instrumental
variable analyses and to study causal effects when there
is a failure of compliance to treatment (see, e.g., Jin and
Rubin [25]), where it is often assumed that compliance
to treatment Z = 1 is better when assigned to Z = 1
than when assigned to treatment Z = 0, and vice versa.
Monotonicity assumptions can be applied to biomark-
ers, outcomes, and any other relevant variables that are
measured after treatment has been assigned.
Individual-level monotonicity assumptions imply an
ordering for two counterfactual random variables mea-
sured on the same subject, which places constraints on
the joint distribution of counterfactuals and aids identifi-
ability by ruling out certain combinations of outcomes. In
a study comparing low-dose vitamin D supplementation
(Z = 1) to placebo (Z = 0) for preventing occurrence
of an episode of clinical depression (Y = 1), it might be
reasonable to assume that P(Yi,1 ≤ Yi,0) = 1 for all i
since supplementation is very unlikely to result in a higher
chance of clinical depression. Under this assumption, the
counterfactual pair (Y0,Y1) is fully known for subjects
with Z = 1,Y = 1 (1 = Y1 ≤ Y0 = 1) and Z =
0,Y = 0 (0 = Y0 ≥ Y1 = 0), so that P(Y1 = 0 |Y0 = 0) =
1 and P(Y0 = 1 |Y1 = 1) = 1. While individual-level
monotonicity assumptions involve the joint distribution of
subject-specific counterfactual variables and are therefore
untestable in general, they often have testable implica-
tions. In our example, the assumption P
(
Yi,1 ≤ Yi,0
) = 1
implies that P(Y1 = 1) ≤ P(Y0 = 1), which is testable by
considering the difference between P(Y = 1 | Z = 1) and
P(Y = 1 | Z = 0).
Distribution-level monotonicity assumptions are
weaker than individual-level assumptions, and give a
stochastic ordering to counterfactual random variables.
This ordering may relate the distributions two differ-
ent counterfactuals (e.g., S1 ≥s S0), or two conditional
distributions of the same counterfactual (e.g., S1 | Y0 =
0 ≥s S1 | Y0 = 1). For example, assuming that S1 | Y1 =
1 ≤s S1 | Y0 = 1 constrains the (nonidentifiable) CDF of
S1 | Y0 = 1 to lie to the right of the (identifiable) CDF
of S1 | Y1 = 1, thereby restricting the family of densities
f (s1 | Y0 = 1) and potentially allowing (13) and (14) to be
bounded using observed data.
In general, monotonicity is most likely to hold
for intervention-placebo comparisons when the inter-
ventions (such as vaccines and educational/behavioral
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interventions) have few or no negative side effects. Mono-
tonicity assumptions are less likely to be defensible for
therapeutic agents that can be toxic or harmful (e.g.,
some types of chemotherapy) or when comparing two
active treatments. Evaluating the validity of monotonicity
assumptions can be tricky; for instance, in a re-analysis
of data from the Lipid Research Clinics Coronary Pri-
mary Prevention Trial (LRC-CPPT) originally analyzed by
Efron and Feldman [26], Goetghebeur and Molenberghs
[27] observed that subjects with higher observed compli-
ance to active treatment (cholestyramine, a cholesterol-
lowering drug) were estimated to have worse response to
lower doses than those with lower observed compliance,
while the opposite was true for subjects with high com-
pliance to placebo. They argued that this effect may have
been due to the unpleasant gastrointestinal side effects of
cholestyramine, which reduced compliance among those
who had the least to gain by remaining compliant.
Auxiliary data and augmented study designs
The fundamental challenge to the statistical identification
of principal stratification estimands is the fact that joint
counterfactual values are not observable. But in some sit-
uations it may be feasible to use auxiliary data, often in
combination with modeling assumptions, to aid identifi-
ability. Auxiliary data may arise from routine data collec-
tion, but they can also be obtained by modifying existing
study designs.
Using baseline predictors
The identifiability problem can be viewed as a missing
data problem, where a subject receiving treatment z has
Yz, Sz, and Aτz observed but Y1−z, S1−z, and Aτ1−z missing.
From this perspective, the goal is to impute the missing
counterfactual values.
One simple imputation method is to use an assumed
regression model to “bridge” across treatments. Suppose
that one can identify baseline covariate vectors U and V
which correlate strongly with S0 and S1 and such that
(U ,V ) can be measured on all subjects. Then one could
consider regression models such as
g[E(S0 | U)] = γ0 + γ1U (15)
g[E(S1 | V )] = β0 + β1V (16)
Model (15) can be fit from subjects randomized to
receive Z = 0 (where S0 is identified) and be used to
impute S0 values for subjects randomized to receive Z =
1. Similarly, model (16) can be fit on those randomized
to receive Z = 1 (where S1 is identified) and produce
imputed S1 values for subjects randomized to receive Z =
0. This approach to imputation is valid since the Ignor-
able Treatment Assignments assumption guarantees that
(S0, S1) ⊥ Z | U ,V . The resulting joint (S0, S1) values can
be used to fit an observed risk model such as
Rz(S0, S1) = α0 + α1z + α2θ(S0, S1) + α3z × θ(S0, S1)
where θ(·) is some pre-defined function of S0 and S1.
As an example, Follmann [28] proposes an imputation
strategy for HIV vaccine trials referred to as Baseline Irrel-
evant Vaccination (BIV). In that context, [SA1] and [SA2]
are assumed to hold so that only S1 values need to be
imputed. To produce a suitable V that strongly correlates
with S1, Follmann suggests administering a rabies vaccine
(the Baseline Irrelevant Vaccination) that does not affect
the eventual vaccine-induced anti-HIV immune response,
but serves as a proxy for each subject’s immune respon-
siveness. The resulting immune activation levels are used
to fit a model such as (16). The BIV approach could also be
adapted to cases where [SA2] does not hold, for instance
an influenza vaccine trial where there is variability in
the influenza-specific immune response due to previous
exposure, and be incorporated into estimation methods
such as that proposed in Zigler and Belin [20].
Augmented study designs
Modified and novel study designs are another potential
source of auxiliary data that can identify principal strati-
fication estimands. The need to identify the joint values
(S0, S1), (Y0,Y1), and so on for each individual leads natu-
rally to the idea of crossover designs [29]. As an illustrative
example, Donovan [30] evaluated the effect of the anticon-
vulsant Divalproex on Oppositional Defiant Disorder or
Conduct Disorder in youth using a double-blind, placebo-
controlled crossover trial. Suppose it were of interest to
identify a surrogate endpoint (e.g., a score from a short
mood questionnaire) for Divalproex’s ability to prevent
episodes of explosive temper. In this setting, occurrence of
the transient outcome is unlikely to interfere with future
measurement of the biomarker of interest so that assump-
tion [SA1] is satisfied. Furthermore, a suitable washout
period between the Divalproex and placebo phases could
minimize carryover effects on both the surrogate and the
clinical endpoints. In this case, one might reasonably view
the crossover data as if they were parallel realizations of
(S0,Y0) and (S1,Y1) from the same subject, permitting full
identification of R1, R0 and their contrasts.
For many clinical trials, it is impractical or unethical
to use a simple crossover design. However, aspects of
the crossover design can be used to augment standard
parallel-arm designs to aid in the evaluation of surrogate
endpoints. In addition to BIV, Follmann [28] also pro-
posed a design modification known as Closeout Placebo
Vaccination (CPV), wherein subjects assigned to receive
the placebo at the beginning of the trial and who remain
uninfected for the duration of the study are given the
active vaccine (“closed out”) upon study completion and
Wolfson and Henn Emerging Themes in Epidemiology 2014, 11:14 Page 7 of 11
http://www.ete-online.com/content/11/1/14
have their biomarker response measured. Wolfson and
Gilbert [2] describe assumptions that permit this “close-
out” value, say Sc1, to be used in place of the unobserved
S1 for these subjects. The key assumption is that of
“time constancy”, i.e., that the underlying process gener-
ating observed S values has not changed over the course
of the study among subjects who received the placebo.
This assumption may be reasonable in trials where the
biomarker of interest measures an aspect of a biological
system which remains relatively stable over time in the
trial population (e.g., the immune system among adults
aged 20 - 50 in an HIV vaccine trial). Figure 1 provides an
overview of the Closeout Placebo Vaccination design.
Data from a Closeout Placebo Vaccination design allow
the identification and estimation of the distribution of
S1 | Y0 = 0, since uninfected placebos are precisely those
with Y0 = 0. Using the relation
f (s1 | Y0 = 1) = f (s1) − f (s1 | Y0 = 0)P(Y0 = 0)P(Y0 = 1)
(17)
it is also possible to identify f (s1 | Y0 = 1) and hence, if
assumptions [SA1] and [SA2] hold, (11)-(14) can be fully
identified using these augmented data.
Information from both baseline covariates and close-
out vaccination can be combined to improve identifiability
and efficiency. Huang et al. [21] present a novel pseudo-
score approach to estimation of R1 and R0 in the con-
text of HIV vaccine trials, and compare the efficiency of
using only baseline covariates with using baseline covari-
ates plus data from Closeout Placebo Vaccination. The
approach accommodates a two-phase sampling strategy
in which a subset of vaccinated subjects and uninfected
placebo recipients are selected to have tissue samples
assayed to obtain information on S.
Closeout designs need not be limited to the context
of vaccine trials; they may be of use in any placebo-
controlled trial where the “time constancy” assumption is
reasonable. These designs are most feasible when either
a) blinding can be maintained during the closeout period,
or b) the biomarker of interest is a physiological param-
eter (e.g., elimination rate of a particular compound)
which is unlikely to be strongly affected if participants are
unblinded to treatment status.
Figure 1 Schematic of a vaccine trial design incorporating closeout placebo vaccination. The four horizontal lines represent four subjects
(two each assigned to placebo and active vaccine at time T = 0). Subjects have biomarker Sobs measured at time τ , identifying S0 and S1 for
placebo and vaccine recipients, respectively; the counterfactual biomarker values (S1 and S0 respectively) remain unidentified, as indicated by ‘?’.
Subjects with the solid diamond represent those infected during the trial (yielding Y0 = 1 and Y1 = 1). Subjects assigned to placebo and uninfected
during the trial (i.e., those with Y0 = 0) are eligible for closeout vaccination at the end of the study at time T = t. Post-closeout vaccination
biomarker measurements Scloseout are obtained on these subjects at time T = t + τ . The dashed curved arrow represents the “time constancy”
assumption that allows Scloseout to be used to identify S1, by definition the counterfactual measurement that would have been obtained at T = τ
under assignment to the active vaccine. For ease of readability, this figure does not represent subjects who were infected prior to τ (i.e., those with
Aτ = 0) and who would have Y = 1 and S undefined.
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Example scenarios
Thus far, we have described key assumptions and sources
of auxiliary data that help identify principal stratification
estimands and thereby facilitate assessment of the surro-
gate value of a biomarker. In this section, we present four
hypothetical scenarios where one might wish to assess
surrogate value. We discuss which of the above assump-
tions and augmented designs are plausible or feasible in
each scenario, and show that assessing surrogate value via
principal stratification in the four scenarios is straight-
forward, moderately difficult, somewhat challenging, and
extremely challenging, respectively. Table 1 summarizes
the results of this section.
[ Scenario 1 - HIV vaccine trial ]
Clinical endpoint Y : Infection with HIV
Proposed surrogate S: HIV-specific immune response
For HIV vaccine trials, the surrogate endpoint problem
consists of identifying specific immune response pro-
files that quantify the degree to which a subject is pro-
tected against HIV infection after receiving the vaccine.
As detailed in several sections of this paper, HIV vaccine
trials possess characteristics that simplify the assessment
of surrogate value and may even in some cases allow full
statistical identification of principal stratification-based
estimands.
Assumptions assessment: [SA1]: Many previous HIV
vaccines required subjects to undergo a sequence of injec-
tions, and hence peak immunity was not established
until several months after the start of the trial. Since
the immune response to the vaccine cannot be measured
in the presence of an active HIV infection, [SA1] may
be questionable. Future formulations may require fewer
injections and induce relevant immune responses more
quickly, so that [SA1] may be valid.
[SA2]: As described in the section introducing [SA2],
healthy volunteers who receive a placebo vaccine have no
HIV-specific immune cells and hence it is reasonable to
assume that S0 = c, so [SA2] holds.
[SA3]: Since vaccines are designed for prevention of dis-
ease in the general population, tolerance for vaccine side
effects is low and it may be plausible to assume a mono-
tonic vaccine treatment effect, e.g., P(Y1 ≤ Y0) = 1.
However, it is worth noting that some early vaccine trials
showed weak evidence of an “enhancement” effect where
vaccinated subjects were in fact more likely to be infected
than placebo recipients. While this would negate [SA3]
andmake surrogate assessmentmore challenging, in prac-
tice it is unlikely that there would be great interest in
understanding the relevant surrogates for such a vaccine.
Auxiliary data and augmented designs: As detailed
above, the Baseline Irrelevant Vaccination and Closeout
Placebo Vaccination designs were proposed first in the
context of HIV vaccine trials, and so may provide useful
tools for identifying principal stratification estimands.
[ Scenario 2 - Influenza vaccine trial ]
Clinical endpoint Y : Flu infection in a given season
Proposed surrogate S: Immune response to vaccine
Rapid prototyping of influenza vaccines relies on the
identification of reliable immune biomarkers which reflect
the degree of protection offered by the vaccine. Trials of
influenza vaccines share many characteristics with HIV
vaccine trials, with the chief exception being that subjects
enrolled in these trials are likely to have been previously
infected with influenza.
Assumptions assessment:
[SA1]: Participants in influenza vaccine trials may
become infected with the flu before their immune
response to the vaccine is measured. However, the rela-
tively short time frame between influenza vaccination and
peak immune response (reported as 4 - 9 days [31]) may
limit the degree to which this assumption will be violated.
[SA2]: Most subjects enrolled in influenza vaccine tri-
als will have been infected previously with influenza, and
so there is likely to be variability in S0 due to different lev-
els of immune cross-reactivity with the strain of interest.
[SA2] is therefore unlikely to be plausible.
[SA3]: Influenza vaccines are unlikely to cause harm,
and are generally not believed to increase susceptibility to
influenza infection. However, some caution is warranted
before blindly adopting the monotonicity assumption
[SA3]; for instance, a trial participant who remains
infection-free after multiple exposures to influenza-
infected individuals may conclude that he or she received
the active vaccine and hence take fewer precautions to
prevent future exposure, increasing his or her likelihood
of infection.
Table 1 Difficulty of evaluating surrogate endpoints in four scenarios
Scenario Endpoint Y Possible surrogate S [SA1] [SA2] [SA3] BP Closeout Difficulty
HIV vaccine trial Infection with HIV Immune response ∼   ∼  Low/Moderate
Influenza vaccine trial Infection with influenza Immune response    ∼ Moderate
Surgery for CHF Survival Admission-free survival  ∼ Moderate/High
Treatment for CVD Survival Blood biomarkers ∼ ∼ High
 indicates assumptions ([SA1]-[SA3]) and auxiliary data collection strategies (BP = use of baseline predictors, Closeout = closeout design) which will typically be
plausible in each scenario. ∼ indicates assumptions and strategies which may be plausible in certain special cases which are described in the text.
Wolfson and Henn Emerging Themes in Epidemiology 2014, 11:14 Page 9 of 11
http://www.ete-online.com/content/11/1/14
Auxiliary data and augmented designs: Closeout
placebo vaccination may be possible in influenza vaccine
trials, though its value may be limited if a substantial frac-
tion of study subejcts acquire influenza during the study
and hence are ineligible to be “closed out”. A modifica-
tion of the baseline predictor strategy also is possible [28],
since the pre-vaccination levels of the biomarker of inter-
est may be very highly correlated with S0, and can be
measured on all subjects.
[ Scenario 3 - Randomized trial of surgical treatments
for patients with congestive heart failure ]
Clinical endpoint Y : 3-year overall survival
Proposed surrogate S: 1-year admission-free survival
Congestive heart failure is the leading cause of hospital-
ization in people over the age of 65 [32]. There is substan-
tial debate on the best course of management for these
patients, particularly those whose symptoms are relatively
mild. One option is surgery (coronary artery bypass or
valve reconstruction), though these operations carry non-
trivial risk and may not improve long-term outcomes. In
a hypothetical trial evaluating the benefits of immediate
surgery versus, for example, watchful waiting, it may be of
interest to assess whether early outcomes are indicative of
a survival benefit after three years. In this case, a candidate
“biomarker” could be the rate of admission-free survival
at one year, i.e., the proportion of subjects who are still
alive and have not been admitted to a hospital due to heart
failure symptoms.
Assumptions assessment:
[SA1]: Use of an earlier-occurring version of the clinical
endpoint of interest as a potential surrogate, rather than
a lab-measured biomarker, can simplify the assessment of
surrogate value. In this scenario, by definition the clinical
endpoint cannot occur before the candidate surrogate is
measured, and hence [SA1] holds.
[SA2]: Clearly, one would expect variability in 1-year
admission-free survival in both study arms, hence [SA2] is
implausible.
[SA3]: Surgery in patients with congestive heart failure
can be risky, and the amount of morbidity and mortal-
ity associated with immediate surgery could conceivably
outweigh the improvement in symptoms experienced by
those whose surgeries are successful. Hence the mono-
tonicity assumption is unlikely to hold for either 1-year
admission-free survival or 3-year overall survival.
Auxiliary data and augmented designs: The major
demographic factors associated with admission and sur-
vival rates for heart failure have been studied extensively,
so it may be feasible to use these factors to construct a
model to impute S0 and S1 among subjects randomized to
treatments Z = 1 and Z = 0 respectively.
Due to the temporal nature and ordering of the pro-
posed surrogate and clinical outcome, crossover and
closeout designs are not possible in this setting.
[ Scenario 4 - Cardiovascular drug therapy ]
Clinical endpoint Y : Occurrence of cardiovascular
events
Proposed surrogate S: Various blood-based biomarkers
For many years there has beenmuch interest in identify-
ing biomarkers of cardiovascular disease [33,34]. Assess-
ing whether these biomarkers are valid surrogates for the
clinical effects of cardiovascular disease medications can
be challenging. Among many difficulties, the biomark-
ers themselves might not be well understood until years
after their discovery; such was the case for soluble throm-
bomodulin 2 (ST2) [33] and C-reactive protein (CRP)
[35], and may be the case for many currently proposed
biomarkers (see, e.g., Table eight in Vasan [34]). Further,
the mechanisms of action of many relatively successful
cardiovascular medications have not yet been described
fully.
Assumptions assessment:
[SA1]: Treatments for cardiovascular disease may not
achieve their full effects on biomarkers for weeks or
months, during which time cardiovascular events may
occur and thereby preclude the measurement of the mark-
ers of interest. Violations of [SA1] are particularly likely in
studies of populations where the rate of severe cardiovas-
cular disease and the incidence of cardiovascular events is
high.
[SA2]: Many cardiovascular biomarkers of interest are
nonspecific, reflecting changes in a number of biologi-
cal processes. For example, CRP is a generalized marker
of inflammation, and hence may be elevated due to tran-
sient conditions such as a bacterial or viral infection
or noncardiovascular chronic conditions such as cancer
malignancy. [SA2] is therefore unlikely to be satisfied.
[SA3]: Treatment of cardiovascular disease has pro-
gressed to the point where several effective treatments
exist and new drugs are evaluated against standard-of-
care regimens. Therefore, in many cases it may be unrea-
sonable to assume that treatment effects on either the
biomarker of interest or the clinical endpoint are mono-
tonic in favor of the new drug. But when comparing
standard-of-care and an “augmented” standard-of-care
including a new medication, [SA3] may be warranted
provided there are few concerns about the medications
involved producing a harmful interaction.
Auxiliary data and augmented designs: When two dif-
ferent active treatments are being compared, closeout
designs may be difficult to justify because the biomarker
levels achieved by an individual that was randomized to
treatment Z = 0 and was subsequently “closed out” with
treatment Z = 1 may not reflect the levels that would
have been achieved had that individual been randomized
to treatment Z = 1 initially. However, a closeout design
analogous to Closeout Placebo Vaccination may be feasi-
ble when treatment Z = 0 is standard-of-care and Z = 1
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is standard-of-care plus a new medication. In all cases,
the “time constancy” assumptions that allow biomark-
ers measured at the end of the study to substitute for
biomarkers measured shortly after randomization must
be evaluated carefully, since the physiological systems
influencing biomarkers may undergo rapid changes with
aging and as cardiovascular disease progresses. The base-
line predictor approach requires fewer assumptions and
trial design modifications, but its utility may be limited
since the predictors ofmost cardiovascular biomarkers are
often poorly understood.
Conclusion
The principal stratification approach to evaluating sur-
rogate endpoints relies on estimands that capture causal
effects of interest but may not be statistically identifiable.
Exploring the identifiability of these estimands under a
variety of assumptions reveals that the nature of the data-
generating process and the constraints imposed by ran-
domized trial designs have a major impact on the ability
to use statistical modeling to assess the value of surro-
gate endpoints. When many of the assumptions outlined
above are plausible or auxiliary data are available, princi-
pal stratification estimands may be identifiable or nearly
identifiable such that a straightforward sensitivity analysis
is possible. In such settings, statistical analysis of data aris-
ing from a well-designed Phase III trial (possibly incorpo-
rating one of the aforementioned enhanced study designs)
may provide insights into surrogacy. Conversely, when
biomarkers are not well understood, when the potential
side effects of the proposed treatment are poorly charac-
terized, or when treatment effects on biomarkers are only
fully achieved a long time after randomization, it may not
be possible to identify the relevant risk estimands without
several strong and untestable assumptions. In these more
difficult cases, statistical analyses will be of limited use
in the evaluation of candidate surrogates, and researchers
must rely more heavily on findings from laboratory and
clinical science.
Though one might be tempted to conclude from this
paper that the search for reliable surrogate endpoints is
doomed to failure in many areas of biomedical research,
we do not subscribe to such a pessimistic view. Rather, we
believe that increased awareness of how the characteris-
tics of diseases, treatments, and study logistics combine to
affect the ability to identify surrogate endpoints can assist
with the planning, implementation, and analysis of major
trials. By incorporating novel design concepts and by care-
fully assessing the validity of key assumptions, we believe
that future studies will be able to coax surrogate needles
out of the ever-growing biomarker haystack.
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